1019446-59-3

Basic information

• Product Name: 3-(cyclohexylmethoxy)benzaldehyde
• Synonyms: 3-(cyclohexylmethoxy)benzaldehyde;3-(Cyclohexylmethoxy)Benzaldehyde(WXC04811)
• CAS NO: 1019446-59-3
• Molecular Formula: C₁₄H₁₈O₂
• Molecular Weight: 218.29152
• Mol File: 1019446-59-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(cyclohexylmethoxy)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(cyclohexylmethoxy)benzaldehyde(1019446-59-3)
• EPA Substance Registry System: 3-(cyclohexylmethoxy)benzaldehyde(1019446-59-3)

Safety Data

• Hazardous Substances Data: 1019446-59-3(Hazardous Substances Data)

Upstream product

• 100-83-4 meta-hydroxybenzaldehyde 
• 2550-36-9 Cyclohexylmethyl bromide 

Downstream Products

• 1141779-32-9 3-(3-(cyclohexylmethoxy)phenyl)-3-hydroxypropanenitrile 
• 1141781-63-6 C₁₆H₂₂O₂ 

Relevant articles and documents

Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy

In anti-tumour therapy, the toll-like receptor 2/4 (TLR2/4) signalling pathway has been a double-edged sword. TLR2/4 agonists are commonly considered adjuvants for immune stimulation, whereas TLR2/4 antagonists demonstrate more feasibility for anti-tumour therapy under specific chronic inflammatory situations. In individuals with cancer retaliatory proliferation and metastasis after surgery, blocking the TLR2/4 signalling pathway may produce favourable prognosis for patients. Therefore, here, we developed a small-molecule co-inhibitor that targets the TLR2/4 signalling pathway. After high-throughput screening of a compound library containing 14 400 small molecules, followed by hit-to-lead structural optimisation, we finally obtained the compound TX-33, which has effective inhibitory properties against the TLR2/4 signalling pathways. This compound was found to significantly inhibit multiple pro-inflammatory cytokines released by RAW264.7 cells. This was followed by TX-33 demonstrating promising efficacy in subsequent anti-tumour experiments. The current results provide a novel understanding of the role of TLR2/4 in cancer and a novel strategy for anti-tumour therapy.

ALKOXY COMPOUNDS FOR DISEASE TREATMENT

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.